Inventiva (NASDAQ:IVA) Stock Price Up 6.7% – Here’s Why

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) were up 6.7% on Thursday . The stock traded as high as $6.59 and last traded at $6.5840. Approximately 238,937 shares traded hands during mid-day trading, a decline of 57% from the average daily volume of 553,148 shares. The stock had previously closed at $6.17.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Wolfe Research upgraded Inventiva to a “strong-buy” rating in a report on Thursday, November 6th. Leerink Partners initiated coverage on shares of Inventiva in a research note on Monday, January 12th. They set an “outperform” rating and a $12.00 target price for the company. Barclays initiated coverage on Inventiva in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 price target for the company. Guggenheim lowered their price objective on Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Finally, HC Wainwright set a $24.00 target price on shares of Inventiva and gave the company a “buy” rating in a research note on Wednesday, January 28th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $16.22.

Inventiva Price Performance

The company’s 50-day simple moving average is $5.51 and its two-hundred day simple moving average is $5.07.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in IVA. Paradigm Biocapital Advisors LP purchased a new stake in Inventiva in the 4th quarter worth $18,600,000. ADAR1 Capital Management LLC bought a new position in Inventiva during the fourth quarter valued at $12,601,000. Millennium Management LLC lifted its holdings in shares of Inventiva by 2,267.7% in the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after acquiring an additional 2,540,540 shares during the last quarter. UBS Group AG lifted its stake in shares of Inventiva by 28,881.6% in the 4th quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after purchasing an additional 2,634,580 shares during the last quarter. Finally, SymBiosis Capital Partners LLC purchased a new position in Inventiva during the fourth quarter worth $12,090,000. 19.06% of the stock is currently owned by institutional investors.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.